Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
2.090
0.00 (0.01%)
Mar 31, 2025, 10:46 AM EDT - Market open
Company Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors.
The company is headquartered in Doylestown, Pennsylvania.
Aprea Therapeutics, Inc.
| Country | United States |
| Founded | 2006 |
| IPO Date | Oct 3, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Oren Gilad |
Contact Details
Address: 3805 Old Easton Road Doylestown, Pennsylvania 18902 United States | |
| Phone | 617 463 9385 |
| Website | aprea.com |
Stock Details
| Ticker Symbol | APRE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001781983 |
| CUSIP Number | 03836J102 |
| ISIN Number | US03836J2015 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Oren Gilad Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| John P. Hamill CPA | Senior Vice President, Chief Financial Officer, Principal Accounting Officer and Secretary |
| Dr. Lars B. Abrahmsen Ph.D. | Senior Vice President and Chief Scientific Officer |
| Brian Wiley | Senior Vice President of Corporate Development and Strategy |
| Dr. Michel Afargan Ph.D. | Head of Pharmacology Development |
| Ze'ev Weiss B.Sc., C.P.A. | Chief Business Advisor |
| Andrea Epstein | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 8-K | Current Report |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Nov 14, 2024 | SCHEDULE 13G | Filing |
| Nov 8, 2024 | 8-K | Current Report |
| Nov 8, 2024 | 424B5 | Filing |